Skip to main content
TipRanks
Go Ultimate75% OFF

Astrana Health (ASTH) AI Stock Analysis

283 Followers
ASTH

Astrana Health

(NASDAQ:ASTH)

Select Model
Rating:60Neutral
Price Target:$30.00â–²(3.81% Upside)
Action:reiterated
Date:11/07/26

ASTH scores 60 mainly due to strong financial scale-up and improving leverage, supported by a positive earnings call (record results, maintained guidance, and continued deleveraging). The score is held back by meaningful margin compression and weakening free-cash-flow growth, plus weak technical positioning with the stock trading below key moving averages and a sub-40 RSI. Valuation is moderately unfavorable with a ~32 P/E and no dividend yield provided.

Positive Factors
Exceptional Revenue GrowthAstrana is scaling rapidly, with TTM revenue growth accelerating to 175.8%. This expansion indicates strong demand for its value-based care platform and broadening operating base, creating greater opportunity to spread fixed infrastructure costs and deepen relationships with providers, payers, and managed populations.
Negative Factors
Severe Margin CompressionRevenue growth has not translated proportionally into profitability, as gross and net margins have fallen materially over time. Persistently thin margins leave less room for medical-cost volatility, integration spending, or execution setbacks, and they make sustained operating leverage essential to convert scale into durable earnings.

Astrana Health (ASTH) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%ASTH+24.46%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.42B
Dividend Yield
―
Average Volume (3M)
376.53K
Price to Earnings (P/E)
26.6
Beta (1Y)
1.15
Revenue Growth
35.05%
EPS Growth
463.11%
Country
US
Employees
3,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Astrana Health Business Overview & Revenue Model

Company Description

Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985. This company delivers medical services throughout the United States, operating...

How the Company Makes Money

Astrana Health makes money primarily by participating in and supporting value-based healthcare arrangements in which it is financially tied to the total cost and quality of care for defined patient populations. Key revenue and earnings drivers genera...

Astrana Health Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-25.92%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive overall, supported by record revenue and adjusted EBITDA, organic EBITDA growth, strong free cash flow, significant debt reduction, favorable Medicare and Texas performance, Prospect integration progress, and multiple growth initiatives. Management also maintained its full-year outlook and reiterated at least mid-teens medium-term adjusted EBITDA growth. The principal challenges were Medicaid membership attrition and medical cost pressure, expected fourth-quarter seasonality, ACO program transition considerations, the previously disclosed material weakness, and the ongoing cybersecurity investigation. Highlights significantly outweighed the lowlights.

Positive Updates

Record Quarterly Revenue and Adjusted EBITDA
Third-quarter revenue reached a record $1.02 billion, up 7% year over year. Adjusted EBITDA was a record $77.2 million, up 13% year over year and near the high end of the $72.5 million to $77.5 million guidance range. Adjusted diluted EPS was $0.71 and net income attributable to Astrana was $13 million.

Negative Updates

Medicaid and Exchange Membership Attrition
Capitation revenue grew 8.5% despite Medicaid and Exchange membership attrition. Medicaid attrition was expected to be at the middle to high end of the 10% to 15% range assumed at the beginning of the year, and the company currently anticipates a 10% to 15% decline in Medicaid membership in 2027.

Company Guidance

Astrana is maintaining the midpoint of its full year outlook and now expects revenue of $3.9 billion to $4 billion, adjusted EBITDA of $261 million to $274 million, and free cash flow of $107.5 million to $130 million; fourth-quarter revenue is expected between $939 million and $1.04 billion and adjusted EBITDA between $48.5 million and $61.5 million. The company expects full year G&A to remain around approximately 6.2% of revenue, overall medical cost trend to remain around the approximately 5.2% assumption embedded in full year guidance, and to approach 2x net leverage by year end. It expects at least mid teens annual adjusted EBITDA growth over the medium term, approximately 82% of capitation revenue under full risk arrangements by year end, 10 to 15% decline in Medicaid membership in 2027, Medicare Advantage margins to remain stable into 2027, weighted average paid star rating to improve modestly in 2027 versus 2026 and remain relatively stable in 2028, and at least mid to high teens membership growth in its ACO programs going into 2027.

Astrana Health Financial Statement Overview

Summary

Top-line growth is exceptionally strong (TTM revenue growth 175.8%), and the balance sheet appears improved with low leverage (debt-to-equity 0.13). Offsetting that, profitability has compressed sharply (gross margin down to 7.0% TTM; net margin 1.4%), and free cash flow is positive but weakening (TTM FCF growth -37.3%) with thin cash conversion.

Income Statement

62Positive

Balance Sheet

68Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.91B3.18B2.03B1.39B1.14B773.91M
Gross Profit396.48M295.78M271.39M214.96M199.48M177.77M
EBITDA214.34M135.28M141.84M123.69M112.08M100.66M
Net Income53.13M22.49M43.15M60.72M45.17M68.92M
Balance Sheet
Total Assets2.34B2.22B1.35B933.36M966.21M867.36M
Cash, Cash Equivalents and Short-Term Investments396.23M429.47M290.83M296.31M293.59M286.51M
Total Debt977.38M1.08B471.84M321.01M229.36M200.98M
Total Liabilities1.71B1.66B840.73M522.59M407.67M356.72M
Stockholders Equity856.62M779.29M712.72M614.22M542.56M448.17M
Cash Flow
Free Cash Flow163.47M104.49M44.17M39.70M59.19M51.11M
Operating Cash Flow182.25M114.60M52.20M68.23M82.13M70.33M
Investing Cash Flow-18.77M-539.00M-192.40M-65.52M-7.11M16.54M
Financing Cash Flow-177.36M569.35M135.15M3.42M-20.09M-47.75M

Astrana Health Technical Analysis

Technical Analysis SentimentNegative
Last Price28.90

Price Trends

50DMA35.82Negative
100DMA38.12Negative
200DMA34.48Negative

Market Momentum

MACD-1.80Positive
RSI28.90Positive
STOCH7.78Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASTH, the sentiment is Negative. The current price of 28.90 is below the 20-day moving average (MA) of 34.69, below the 50-day MA of 35.82, and below the 200-day MA of 34.48, indicating a bearish trend. The MACD of -1.80 indicates Positive momentum. The RSI at 28.90 is Positive, neither overbought nor oversold. The STOCH value of 7.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASTH.

Astrana Health Risk Analysis

Astrana Health disclosed 78 risk factors in its most recent earnings report. Astrana Health reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We could incur additional costs and expenses resulting from the July 7, 2025, bankruptcy of certain Prospect asset-seller entities and from the effect of the Prospect letter agreement dated July 1, 2025.Q4, 2025
2.The "One Big Beautiful Bill Act" could adversely affect our business and results of operations.Q4, 2025
3.We could incur additional costs and expenses resulting from the July 7, 2025 bankruptcy of certain Prospect asset seller entities and the effect of the Prospect letter agreement dated July 1, 2025.Q2, 2025

Astrana Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ASTH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NUTXNUTX72Outperform$1.11B6.8043.76%―-18.82%17.73%
AGLAGL65Neutral$1.50B-13.66-51.94%―2.02%66.99%
AVAHAVAH65Neutral$2.34B7.28115.53%―16.84%280.13%
INNVINNV62Neutral$1.22B150.253.68%―15.11%―
ASTHASTH60Neutral$1.42B26.556.51%―35.05%463.11%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PIIIPIII49Neutral$13.50M-0.08171.75%―7.54%42.43%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%ASTHNUTXINNVAGLAVAHPIIIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ASTH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ASTHAstrana Health Inc.28.906.3027.88%
NUTXClinigence Holdings Inc162.6425.4318.53%
INNVInnovage Holding Corp.9.163.8472.18%
AGLAgilon Health Inc90.2474.21462.94%
AVAHAveanna Healthcare Holdings Inc11.011.9721.79%
PIIIP3 Health Partners Inc.1.69-4.25-71.55%

Astrana Health Corporate Events

Financial DisclosuresM&A Transactions

Astrana Health Reports Strong Third-Quarter Revenue and Earnings Growth

Positive
Nov 5, 2026

Astrana Health is a physician-centric, technology-enabled healthcare company that combines proprietary technology, aligned physician partnerships and integrated care delivery to help providers deliver accessible, high-quality, high-value care. On Nov...

Business Operations and StrategyRegulatory Filings and Compliance

Astrana Health Showcases AI-Driven Value-Based Care Strategy

Positive
Sep 23, 2026

On September 23, 2026, Astrana Health, Inc. updated a corporate presentation it plans to use at investor conferences and meetings, formally furnishing the materials via a regulatory filing without treating them as filed financial disclosures. The pre...

Business Operations and StrategyFinancial Disclosures

Astrana Health Updates Investor Presentation, Highlights Risk Model

Positive
Sep 15, 2026

On September 15, 2026, Astrana Health updated its corporate investor presentation for use at conferences and meetings, outlining its delegated risk and financial model as an alternative to traditional fee-for-service and value-based care structures....

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026